Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, Chicago, Illinois 60637, USA.
Section of General Internal Medicine, University of Chicago, Chicago, Illinois 60637, USA.
J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3411-e3419. doi: 10.1210/clinem/dgac215.
Many patients with hypothyroidism receive suboptimal treatment that may affect hospital outcomes.
This work aimed to identify differences in hospital outcomes between patients with and without hypothyroidism.
A retrospective cohort study, using the propensity score-based fine stratification method to balance covariates, was conducted using a large, US-based, commercial claims database from January 1, 2008 to December 31, 2015. Participants included patients aged 64 years and younger who had a thyrotropin (TSH) level collected before a hospital admission. Covariates included age, sex, US region, type of admission, year of admission, and comorbidities. Exposure included clinical hypothyroidism, which was divided into 4 subgroups based on prehospitalization TSH level: low (TSH < 0.40 mIU/L), normal (TSH 0.40-4.50 mIU/L), intermediate (TSH 4.51-10.00 mIU/L), and high (TSH > 10.00 mIU/L).
length of stay (LOS), in-hospital mortality, and readmission outcomes.
A total of 43 478 patients were included in the final study population, of whom 8873 had a diagnosis of hypothyroidism. Those with a high prehospitalization TSH level had an LOS that was 1.2 days longer (95% CI, 1.1-1.3; P = .003), a 49% higher risk of 30-day readmission (relative risk [RR] 1.49; 95% CI, 1.20-1.85; P < .001), and a 43% higher rate of 90-day readmission (RR 1.43; 95% CI, 1.21-1.67; P < .001) compared to balanced controls. Patients with normal TSH levels exhibited decreased risk of in-hospital mortality (RR 0.46; 95% CI, 0.27-0.79; P = .004) and 90-day readmission (RR 0.92; 95% CI, 0.85-0.99; P = .02).
The results suggest suboptimal treatment of hypothyroidism is associated with worse hospital outcomes, including longer LOS and higher rate of readmission.
许多甲状腺功能减退症患者的治疗效果并不理想,这可能会影响住院治疗结果。
本研究旨在确定甲状腺功能减退症患者与非甲状腺功能减退症患者之间住院结局的差异。
本研究采用回顾性队列研究,使用倾向评分的精细分层方法平衡协变量,利用 2008 年 1 月 1 日至 2015 年 12 月 31 日期间美国一家大型商业索赔数据库,纳入年龄在 64 岁及以下、在住院前采集促甲状腺激素(thyrotropin,TSH)水平的患者。协变量包括年龄、性别、美国地区、入院类型、入院年份和合并症。暴露因素包括临床甲状腺功能减退症,根据住院前 TSH 水平将其分为 4 个亚组:低(TSH<0.40mIU/L)、正常(TSH 0.40-4.50mIU/L)、中(TSH 4.51-10.00mIU/L)和高(TSH>10.00mIU/L)。
住院时间(length of stay, LOS)、院内死亡率和再入院结局。
共纳入 43478 例患者作为最终研究人群,其中 8873 例患者诊断为甲状腺功能减退症。与平衡对照组相比,TSH 水平较高的患者 LOS 延长 1.2 天(95%CI,1.1-1.3;P=0.003),30 天再入院风险增加 49%(相对风险[RR]1.49;95%CI,1.20-1.85;P<0.001),90 天再入院率增加 43%(RR 1.43;95%CI,1.21-1.67;P<0.001)。TSH 水平正常的患者院内死亡率(RR 0.46;95%CI,0.27-0.79;P=0.004)和 90 天再入院率(RR 0.92;95%CI,0.85-0.99;P=0.02)降低。
研究结果表明,甲状腺功能减退症治疗效果不理想与住院治疗结局较差相关,包括 LOS 延长和再入院率增加。